



July 9, 2018

News release

Company name: Nichi-Iko Pharmaceutical Co., Ltd.
(Securities code 4541, Tokyo Stock Exchange First Section)
Representative: Yuichi Tamura, President and CEO
Contact: Mitsuyuki Azuma, Operating Officer, President Office
Tel: +81-76-442-7026

Notice regarding business alliance with Sunward Pharmaceutical Pte. Ltd. (Singapore)

To achieve further penetration for the Nichi-Iko brand in the Malaysian and Singaporean markets, key areas of the rapidly growing pharmaceuticals market of the ASEAN region, the Nichi-Iko Pharmaceutical Group has signed a business alliance agreement with Sunward Pharmaceutical Pte. Ltd. (“Sunward” hereinafter). Sunward operates manufacturing and sales sites in both Malaysia and Singapore.

[Nature and specifics of the business alliance]

1. Administrative work pertaining to applications for approval of products to be introduced in Malaysia and Singapore by the Nichi-Iko Pharmaceutical Group
2. Distribution and sale of Nichi-Iko Pharmaceutical products in Malaysia and Singapore

[Sunward Overview]

Name: Sunward Pharmaceutical Pte. Ltd.
Main businesses: Manufacture and sales of pharmaceuticals
Year of establishment: 1968
Location: 11 Wan Lee Road, Singapore 627943
Representative: Jung Jiunn Der
Capital: 3,119,400 Singapore dollars
Number of employees: 315
Revenues: Approximately 15 million US dollars (FY 2017)



Sunward operates manufacturing facilities that meet cGMP manufacturing standards and PIC/S guidelines in both Singapore and Malaysia. It sells high-quality pharmaceuticals for a wide range of therapeutic domains, including respiratory health, in both markets, particularly Malaysia.

For reference: Sunward’s website <http://sunwardpharma.com/>